tldrdailynews.com logo

Roche's Fenebrutinib Achieves Breakthrough Results in Multiple Sclerosis Trials

1 min read
Source: Roche
TL;DR

The website www.roche.com has restricted access for certain IP addresses using Cloudflare, resulting in an error message (Error 1005) that blocks access based on the user's autonomous system number (ASN).

Topics:businesstechnology#access-restriction#cloudflare#error-1005#roche#technology#website-security
Share this article
  1. [Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progress...  Roche
  2. Roche's experimental MS drug hits main goal in one of two key trials  Reuters
  3. Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials  The Wall Street Journal
  4. [Ad hoc announcement pursuant to Art. 53 LR] Roche’s  GlobeNewswire
  5. Roche reports two Phase 3 wins for its BTK inhibitor in multiple sclerosis  Endpoints News

Want the full story? Read the original reporting

Read on Roche